Cancer Chemotherapy and Pharmacology

, Volume 20, Issue 3, pp 198–202 | Cite as

Influence of PSK (Krestin) on resistance to infection ofPseudomonas aeruginosa in tumor-bearing mice

  • Takao Ando
  • Isamu Motokawa
  • Katsuo Sakurai
  • Yoshio Ohmura
  • Takayoshi Fujii
  • Kenichi Matsunaga
  • Chikao Yoshikumi
  • Kikuo Nomoto
Original Articles Pseudomonas Aeruginosa, Infection, Tumor Bearing Mice, Cyclophosphamide, PSK


C3H/He mice were inoculated withPseudomonas aeruginosa by various routes 1 day after X5563 transplantation or 4 days after cyclophosphamide (CY) administration. Administration of PSK (Krestin) i.p. or p.o. to the tumor-bearing mice or CY-treated tumor-bearing mice resulted in an increase in survival rates. ViableP. aeruginosa were inoculated i.v. on day 0 into mice inoculated with tumor cells on day -12 and vaccinated with killedP. aerouginosa on day -10, or into mice inoculated with tumor cell on day -15, treated with CY on day -14 and vaccinated on day -10. Resistance to infection, which is enhanced by vaccination, was depressed by tumor burden or treatment with CY, but such depression was prevented by PSK administration.


Tumor Cell Survival Rate Cancer Research Cyclophosphamide Tumor Burden 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations used












Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bodey GP (1975) Infections in cancer patients. Cancer Treat Rev 2: 89Google Scholar
  2. 2.
    Bradner WT, Clarke DA, Stock CC (1958) Stimulation of host defense against experimental cancer: I. Zymosan and sarcoma 180 in mice. Cancer Res 18: 347Google Scholar
  3. 3.
    Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F (1969) Inhibition of mouse sarcoma 180 by polysaccharides fromLentinus edodes (Berk) Sing. Nature 222: 687Google Scholar
  4. 4.
    Dubos RJ, Schaedler RW (1956) Reversible changes in the susceptibility of mice to bacterial infections: I. Changes brought about by injection of pertussis vaccine or of bacterial endotoxins. J Exp Med 104: 53Google Scholar
  5. 5.
    Fauve RM, Hevin B (1974) Immunostimulation with bacterial phospholipid extracts. Proc Natl Acad Sci USA 71: 573Google Scholar
  6. 6.
    Harvath L, Anderson BR, Zander AR, Epstein RB (1976) Combined pre-immunization and granulocytes transfusion therapy for treatment of pseudomonas septicemia in neutropenic dogs. J Lab Clin Med 87: 840Google Scholar
  7. 7.
    Hersh EM, Bodey GP, Nies BA, Freireich EJ (1965) Causes of death in acute leukemia. J Am Med Assoc 193: 105Google Scholar
  8. 8.
    Inagaki J, Rodriguez V, Bodey GP (1974) Causes of death in cancer patients. Cancer 33: 568Google Scholar
  9. 9.
    Maderazo EG, Anton TF, Ward PA (1978) Serum-associated inhibition of leukotaxis in humans with cancer. Clin Immunol Immunopathol 9: 166Google Scholar
  10. 10.
    Mizuno D, Yoshioka O, Akamatsu M, Kataoka T (1968) Antitumor effect of intracutaneous injection of bacterial lipopolysaccharide. Cancer Res 28: 1531Google Scholar
  11. 11.
    Nauta EH (1979) Infection in the compromised host. In: Dick G (ed) Immunological aspects of infectious diseases. MTP Press, Lancaster, p 433Google Scholar
  12. 12.
    Nomoto K, Yoshikumi C, Matsunaga K, Fujii T, Takeya K (1975) Restoration of antibody-forming capacities by PSK in tumor-bearing mice. Gann 66: 365Google Scholar
  13. 13.
    Pennington JE, Reynolds HY, Wood RE, Robinson RA, Levine AS (1975) Use of aPseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am J Med 58: 629Google Scholar
  14. 14.
    Reynolds JA, Kastello MD, Harrington DG, Crabbs CL, Peters CJ, Jemski JV, Scott GH, Di Luzio NR (1980) Glucan-induced enhancement of host resistance to selected infectious diseases. Infect Immun 30: 51Google Scholar
  15. 15.
    Satoh M, Ichimura O, Mitsuno T, Kojima E, Osawa T (1982) Elevation of colony stimulating factors in mouse serum after injection of PSK, an antitumor polysaccharide. J Pharmacobiodyn 5: 818Google Scholar
  16. 16.
    Sher NA, Chaparas SD, Greenberg LE, Bernard S (1975) Effects of BCG,Corynebacterium parvum, and methanol-extraction residue in the reduction of mortality fromStaphylococcus aureus andCandida albicans infection in immunosuppressed mice. Infect Immun 12: 1325Google Scholar
  17. 17.
    Snyderman R, Pike MC, Blaylock BL, Weinstein P (1976) Effects of neoplasms on inflammation: depression of macrophage accumulation after tumor implantation. J Immunol 116: 585Google Scholar
  18. 18.
    tatsukawa K, Mitsuyama M, Takeya K, Nomoto K (1979) Differing contribution of polymprphonuclear cells and macrophages to protection of mice againstListeria monocytogenes andPseudomonas aeruginosa. J Gen Microbiol 115: 161Google Scholar
  19. 19.
    Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) Krestin (PSK). Cancer Treat Rev 11: 131Google Scholar
  20. 20.
    Weibel RE, Vella PP, Mclean AA, Woodhour AF, Davidson WL, Hilleman MR (1977) Studies in human subjects of polyvalent pneumococcal vaccines. Proc Soc Exp Biol Med 156: 144Google Scholar
  21. 21.
    Yoshikumi C, Nomoto K, Matsunaga K, Fujii T, Takeya K (1975) Mouse strain difference in the expression of antitumor activity of PSK. Gann 66: 649Google Scholar
  22. 22.
    Young LS, Meyer RD, Armstrong D (1973)Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med 79: 518Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Takao Ando
    • 1
  • Isamu Motokawa
    • 1
  • Katsuo Sakurai
    • 1
  • Yoshio Ohmura
    • 1
  • Takayoshi Fujii
    • 1
  • Kenichi Matsunaga
    • 1
  • Chikao Yoshikumi
    • 1
  • Kikuo Nomoto
    • 2
  1. 1.Biomedical Research LaboratoriesKureha Chemical Industry Co., LtdTokyoJapan
  2. 2.Department of Immunology, Medical Institute for Bioregulation ResearchKyushu UniversityFukuokaJapan

Personalised recommendations